Table 1

Relationship between clinicopathologic findings and Ki-67 PI

nMean PISEKrukas-Wallis (Wilcoxon test) PMultiple linear regression − adjusted Pa
Age
 ≤551173.153.06
 55–651368.325.82
 65–754677.612.32
 >753077.453.080.320.91
Sex
 Female5675.692.34
 Male4476.092.270.920.152
MSI
 MSI-H3190.111.19
 MSI-L2969.473.12
 MSS4069.462.32<0.00010.0004
Side
 Left5171.172.32
 Right4880.842.180.0020.705
TIL
 Negative6271.232.08
 Positive3883.432.2<0.00010.618
Dukes’ stage
 A1476.085.09
 B4777.712.34
 C2275.353.02
 D1568.384.570.260.054
Grade
 Moderate/Well7073.321.98
 Poorly differentiated3081.802.920.040.34
Type
 Adenocarcinoma7973.361.89
 Mucinous2184.892.520.0040.748
TP53 LOHb
 Negative4177.292.69
 Positive3869.242.560.0150.322
K-ras mutationb
 Negative6074.222.43
 Positive1768.993.710.21
TGFβ RII mutationc
 Negative1190.777.50
 Positive2089.755.890.39
BAX mutationc
 Negative1589.971.35
 Positive1690.241.970.46
  • a Linear regression model was applied to the squared transformation of Ki-67 percentage that was closer to the normal distribution. Variables included in the model are patient age and sex, MSI, TIL status, stage, tumor site, stage, grade, type, and TP53 LOH.

  • b Not all tumors were available for mutation testing.

  • c Only MSI-H cancers were tested for mutations in repetitive DNA sequences of these genes.